GlassScriptPhysician profile
Sunita Jain
NPI 1184691974
$2,738.49
in general payments reported to CMS, 2019-2025
24 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $225 · 2021: $16.25 · 2022: $303 · 2023: $465 · 2024: $488 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $506.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $326.58 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $248.73 | 2019-2025 | |
| Lilly USA, LLC | $222.04 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $202.49 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.54 | 2020-2025 | Jardiance, Ofev |
| Abbvie INC. | $179.72 | 2023-2025 | |
| Dexcom, INC. | $135.96 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $128.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $93.66 | 2019-2020 | |
| Exact Sciences Corporation | $88.04 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $71.38 | 2025 | Repatha, Otezla |
| Novo Nordisk INC | $56.73 | 2022 | |
| Amarin Pharma, INC. | $55.14 | 2019 | |
| Phathom Pharmaceuticals, INC. | $37.49 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.48 | 2019 | |
| Optinose US, INC. | $26.79 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $25.69 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $25.24 | 2019 | |
| Eisai INC. | $21.50 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2019 | |
| Harmony Biosciences LLC | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunita Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.